

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/020,923	12/19/2001	James Thacker	38599.0015	9929
25227 7	590 09/23/2003			
MORRISON & FOERSTER LLP			EXAMINER	
1650 TYSONS BOULEVARD				
SUITE 300			SHAHNAN SHAH, KHATOL S	
MCLEAN, VA	22102			
,			ART UNIT	PAPER NUMBER
			1645 ·	7
			DATE MAILED: 09/23/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/020,923	THACKER, JAMES			
Office Action Summary	Examiner	Art Unit			
	Khatol S Shahnan-Shah	1645			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status					
1) Responsive to communication(s) filed on 19	December 2001 .				
2a) This action is FINAL. 2b) Th	☐ This action is FINAL. 2b)☐ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1,3,5-19 and 22-24 is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 1, 3, 5-19 and 22-24 are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on	11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)					
U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Office Ac	tion Summary	Part of Paper No. 7			

 ι

Application/Control Number: 10/020,923

Art Unit: 1645

DETAILED ACTION

1. Applicant's amendment A, received December 19, 2001, paper # 5 is acknowledged. Specification page 1 was amended. Claims 2, 4, 20 and 21 were canceled. Abstract of disclosure was substituted with a new abstract.

Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1, 3, 5, 23 and 24 are, drawn to a method for amplifying the presence of microorganisms and a method of quantitating microorganisms in a sample, classified in class 435 subclass 34.
 - II. Claims 6-19 are, drawn to a method for identifying or detecting microorganisms using antibodies, classified in class 435, subclass 7.7.
 - III. Claim 22 is, drawn to a method for diagnosing disease, classified in class435, subclass 7.32.
- 3. The inventions are distinct, each from the other because of the following reasons:

 Inventions I-III are drawn to different methods. The inventions are shown to be distinct because they are drawn to distinct methods, which differ in method objectives, method steps, reagents and material used.

Inventions I and II are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as

Application/Control Number: 10/020,923

Art Unit: 1645

claimed because invention II has separate utility such as detecting microorganisms with antibodies whereas group I amplifies the presence of microorganisms only. They are drawn to two different methods with different end results using different reagents.

Inventions I and III are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because invention III has separate utility such as diagnosing disease whereas group I amplifies the presence of microorganisms.

Inventions II and III are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because invention II has separate utility such as detecting microorganisms unrelated to disease.

4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. They have acquired a separate status in the art as a separate subject for inventive effect and requires independent searches. The search of each of the above inventions may overlap but is not co-extensive particularly with regard to the literature search.

Application/Control Number: 10/020,923

Art Unit: 1645

Further, a reference, which would anticipate the invention of one group, would not necessarily anticipate or make obvious the any of the other groups.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Election

6. This application contains claims directed to the following patentably distinct species of the claimed invention:

If applicant elects group II, then there are additional elections of species.

- 1a. Please choose one of method species from claims 6, 7, 11 or 12.
- 7. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 23 and 24 are generic. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after

Page 5

the election, applicant must indicate which are readable upon the elected species. MPEP §

809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct,

applicant should submit evidence or identify such evidence now of record showing the species to

be obvious variants or clearly admit on the record that this is the case. In either instance, if the

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission

may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Conclusion

8. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Khatol Shahnan-Shah whose telephone number is (703) 308-

8896. The examiner can normally be reached on 7:30 AM - 4 PM from Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Lynette F Smith, can be reached on (703) 308-3909. The fax phone number for the organization

where this application or proceeding is assigned to is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0196.

Khatol Shahnan-Shah, BS, Pharm, MS

Biotechnology Patent Examiner

Art Unit 1645

September 12, 2003